

## **Philogen Announces Upcoming Calendar of Corporate Events**

**Siena, Italy, November 3, 2022** - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based therapeutics, announces the calendar of its upcoming corporate events for the remainder of 2022.

### **9 November 2022**

Press Release - Third Quarter Financial Results

### **1 December 2022**

Press Release - Corporate Update

The announcement will be followed by a **Webinar for sell-analysts at 11 am ET / 15 pm GMT / 16 pm CET** on December 1, 2022.

To register to the Webinar, please use the following [link](#), or contact [Philogen@consilium-comms.com](mailto:Philogen@consilium-comms.com).

### **About Philogen**

Philogen is a Swiss-Italian clinical-stage company, listed on the Italian stock exchange, engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and other ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned and has signed agreements with several major pharmaceutical companies. For more information, please visit [www.philogen.com](http://www.philogen.com) and [www.philochem.com](http://www.philochem.com).

### **For more information please contact:**

#### **Philogen**

Dr. Emanuele Puca (Investor Relations)

+41 (0) 43 544 88 00

[emanuele.puca@philogen.com](mailto:emanuele.puca@philogen.com)

#### **Consilium Strategic Communications**

Mary-Jane Elliott, Davide Salvi, Lucie Foster

[Philogen@consilium-comms.com](mailto:Philogen@consilium-comms.com)

---